Bristol Myers Squibb has announced that the FDA has granted approval for Opdivo® (nivolumab) as an adjuvant treatment for individuals aged 12 and above who have undergone complete resection of stage IIB or IIC melanoma. In the cutaneous oncology domain, this is an epoch-making moment. The approval is founded on the Phase 3 CheckMate -76K […]...
FDA Greenlights Opdivo® (Nivolumab) As...
Bristol Myers Squibb has announced that the FDA has granted…
FDA Approves CRCdx® RAS Mutation...
The FDA has given the green light to EntroGen’s CRCdx®…
FoundationOne®CDx Receives FDA Approval As...
Foundation Medicine Inc. has obtained U.S. Food and Drug Administration…